Today in Pharma highlights major deals and alliances, from Novartis’ radioligand therapy agreement with BoomRay to IMA and Abbott’s adult immunization drive.
India renews its global pledge on hepatitis elimination, reaffirming its commitment to end Hepatitis B through prevention, treatment, and equitable care.
The Indian Medical Parliamentarians’ Forum (IMPF) convened the National Policy Summit on MedTech Access on September 22 at Meril Academy, Vapi, under the theme
Super El Nino could strain India's disease surveillance, healthcare infrastructure and pharmaceutical supply chains as climate-linked health risks rise.
Regulatory radar tracks mixed USFDA outcomes as Glenmark and Dishman clear inspections, while Piramal and Cohance face Form-483 observations.
Amgen eyes a wide-open Sjogren's disease market after dazodalibep delivers positive late-stage trial results and meets its primary goal.
Novo Nordisk is reshaping its GLP-1 strategy through oral pills, obesity prevention, and new markets as it expands beyond its injectable-led portfolio.
Anton Paar India has announced NEXUS, a new two-day Industry Knowledge & Technology Platform designed to bring together industry leaders, scientists, researchers and academia to exchange insights on some of the most pressing analytical and manufactur
Roche’s obesity drug enicepatide, shows strong treatment persistence in diabetes patients, delivering 15.5 percent weight loss and significant blood-sugar control at 48 weeks.
CagriSema's latest results highlight how obesity drug development is shifting toward multi-mechanism therapies combining complementary biological pathways.
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")